科倫藥物研究院快速推進抗2019-nCoV藥物研究
格隆匯1月31日丨自2019年12月以來,新型冠狀病毒(2019-nCoV)感染的肺炎確診人數不斷增加,疫情形勢嚴峻,一場沒有硝煙的攻堅戰也在科倫藥物研究院打響。
2020年1月21日晚,在獲得武漢新型冠狀病毒基因序列信息後,科倫藥物研究院緊急組建了抗新型冠狀病毒治療藥物研發攻關小組,通過多次會議討論,確定了藥物開發方向:針對新型冠狀病毒進入並感染細胞的兩個關鍵點進行多肽設計,阻斷新型冠狀病毒的感染過程。
科倫藥物研究院的多肽設計、多肽合成、製劑開發、質量分析、成藥性評價研究團隊的研發人員,主動請戰,取消休假,春節期間三班倒全速推進抗新型冠狀病毒藥物的研究工作。經過近十天的努力,已經完成一組多肽的設計與合成,序貫進入活性篩選、工藝放大、製劑開發和成藥性評價研究。後續還會有多個新的序列完成設計並進入合成和評價階段。
研究院以最大努力,最快速度與疫情和時間賽跑,力爭抗新型冠狀病毒的藥物早日投入使用,為疫情的控制做出貢獻。目前該項目得到四川省發改委、成都市政府的高度關注和重視。
為加快項目的研製進程並儘快投入使用,研究院歡迎與具有以下研製能力的團隊開展合作:多肽批量合成、固相多肽合成、抗冠狀病毒藥物的體內外藥效評價、多肽吸入氣霧劑或吸入用噴霧製劑研製生產能力。聯繫方式如下: 肖亮博士 18583997557
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.